Anti-inflammatory effect of IL-6 receptor blockade in corneal alkali burn

Experimental Eye Research

Volumn 97, Issue 1, 2012, Pages 98-104

  Sakimoto, Tohru ^a   Sugaya, Satoshi ^a   Ishimori, Akiko ^a   Sawa, Mitsuru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Corneal inflammation; IL 6 trans signaling; Interleukin 6 receptor (IL 6R)

Indexed keywords

CYTOKINE RECEPTOR AGONIST; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MR 16 1; PHOSPHATE BUFFERED SALINE; RECOMBINANT INTERLEUKIN 6; SOLUBLE INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAUSTIC BURN; CELL INFILTRATION; CONTROLLED STUDY; CORNEA BURN; CORNEA INJURY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; DOWN REGULATION; DRUG MECHANISM; IMMUNOREACTIVITY; LASER CAPTURE MICRODISSECTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BURNS, CHEMICAL; CELLS, CULTURED; CHEMOKINE CCL2; CORNEAL KERATOCYTES; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EYE BURNS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; KERATITIS; MALE; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM HYDROXIDE; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859506967     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2012.02.015     Document Type: Article

References (34)

1. Adachi Y., Aoki C., Yoshio-Hoshino N., Takayama K., Curiel D.T., Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int. J. Cancer 2006, 119(6):1303-1311.
2. Amano S., Rohan R., Kuroki M., Tolentino M., Adamis A.P. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 1998, 39(1):18-22.
3. Ammit A.J., Moir L.M., Oliver B.G., Hughes J.M., Alkhouri H., Ge Q., Burgess J.K., Black J.L., Roth M. Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292(1):L199-L206.
4. Chang J.H., Han K.Y., Azar D.T. Wound healing fibroblasts modulate corneal angiogenic privilege: interplay of basic fibroblast growth factor and matrix metalloproteinases in corneal angiogenesis. Jpn. J. Ophthalmol. 2010, 54(3):199-205.
5. Cursiefen C., Rummelt C., Küchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000, 19(4):526-533.
6. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 2004, 113(7):1040-1050.
7. Dauer D.J., Ferraro B., Song L., Yu B., Mora L., Buettner R., Enkemann S., Jove R., Haura E.B. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24(21):3397-3408.
8. Ebrahem Q., Minamoto A., Hoppe G., Anand-Apte B., Sears J.E. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest. Ophthalmol. Vis. Sci. 2006, 47(11):4935-4941.
9. Hohki S., Ohguro N., Haruta H., Nakai K., Terabe F., Serada S., Fujimoto M., Nomura S., Kawahata H., Kishimoto T., Naka T. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp. Eye Res. 2010, 91(2):162-170.
10. Izumi-Nagai K., Nagai N., Ozawa Y., Mihara M., Ohsugi Y., Kurihara T., Koto T., Satofuka S., Inoue M., Tsubota K., Okano H., Oike Y., Ishida S. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am. J. Pathol. 2007, 170(6):2149-2158.
11. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001, 15(1):43-58.
12. Kafkala C., Choi J., Zafirakis P., Baltatzis S., Livir-Rallatos C., Rojas B., Foster C.S. Mooren ulcer: an immunopathologic study. Cornea 2006, 25(6):667-673.
13. Kallen K.J. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 2002, 1592(3):323-343.
14. Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149:1-38.
15. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992, 258(5082):593-597.
16. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22(5):347-352.
17. Kobara M., Noda K., Kitamura M., Okamoto A., Shiraishi T., Toba H., Matsubara H., Nakata T. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc. Res. 2010, 87(3):424-430.
18. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., Scheller J., Rose-John S., Kado S., Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 2010, 184(3):1543-1551.
19. Modur V., Li Y., Zimmerman G.A., Prescott S.M., McIntyre T.M. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. 1997, 100(11):2752-2756.
20. Morgan P.B., Efron N., Hill E.A., Raynor M.K., Whiting M.A., Tullo A.B. Incidence of keratitis of varying severity among contact lens wearers. Br. J. Ophthalmol. 2005, 89(4):430-436.
21. Mukaino M., Nakamura M., Yamada O., Okada S., Morikawa S., Renault-Mihara F., Iwanami A., Ikegami T., Ohsugi Y., Tsuji O., Katoh H., Matsuzaki Y., Toyama Y., Liu M., Okano H. Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp. Neurol. 2010, 224(2):403-414.
22. Nakanishi H., Yoshioka K., Joyama S., Araki N., Myoui A., Ishiguro S., Ueda T., Yoshikawa H., Itoh K. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. Am. J. Pathol. 2004, 165(2):471-480.
23. Nishida T., Nakamura M., Mishima H., Otori T., Hikida M. Interleukin 6 facilitates corneal epithelial wound closure in vivo. Arch. Ophthalmol. 1992, 110(9):1292-1294.
24. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21(13):2000-2008.
25. Peters M., Jacobs S., Ehlers M., Vollmer P., Müllberg J., Wolf E., Brem G., Meyer zum Büschenfelde K.H., Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. 1996, 183(4):1399-1406.
26. Pflugfelder S.C., Solomon A., Stern M.E. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000, 19(5):644-649.
27. Philipp W., Speicher L., Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest. Ophthalmol. Vis. Sci. 2000, 41(9):2514-2522.
28. Saika S., Miyamoto T., Yamanaka O., Kato T., Ohnishi Y., Flanders K.C., Ikeda K., Nakajima Y., Kao W.W., Sato M., Muragaki Y., Ooshima A. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am. J. Pathol. 2005, 166(5):1393-1403.
29. Sakimoto T., Yamada A., Kanno H., Sawa M. Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing. Jpn. J. Ophthalmol. 2008, 52(5):393-398.
30. Scheller J., Ohnesorge N., Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand. J. Immunol. 2006, 63(5):321-329.
31. Sugaya S., Sakimoto T., Shoji J., Sawa M. Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn. J. Ophthalmol. 2011, 55(3):277-282.
32. Suzuki M., Hashizume M., Yoshida H., Mihara M. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol. Int. 2010, 30(3):309-315.
33. Uchiyama Y., Yorozu K., Hashizume M., Moriya Y., Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol. Pharm. Bull. 2008, 31(6):1159-1163.
34. Yang S., Hu S., Choudhry M.A., Rue L.W., Bland K.I., Chaudry I.H. Anti-rat soluble IL-6 receptor antibody down-regulates cardiac IL-6 and improves cardiac function following trauma-hemorrhage. J. Mol. Cell. Cardiol. 2007, 42(3):620-630.